S&P 500   3,741.80 (-0.71%)
DOW   30,853.89 (-0.23%)
QQQ   300.18 (-1.29%)
AAPL   118.73 (-1.17%)
MSFT   227.17 (+0.19%)
FB   258.48 (+0.33%)
GOOGL   2,039.27 (+0.26%)
TSLA   567.35 (-8.70%)
AMZN   2,918.60 (-1.98%)
NVDA   474.65 (-4.07%)
BABA   230.23 (-0.12%)
CGC   29.05 (-6.32%)
GE   13.32 (-1.84%)
MU   84.48 (+0.18%)
NIO   34.60 (-11.91%)
AMD   75.35 (-3.09%)
T   29.42 (+1.73%)
F   11.90 (-0.25%)
ACB   8.96 (-8.76%)
DIS   185.12 (-1.55%)
BA   218.45 (-2.79%)
NFLX   502.77 (-1.67%)
BAC   36.50 (+0.00%)
S&P 500   3,741.80 (-0.71%)
DOW   30,853.89 (-0.23%)
QQQ   300.18 (-1.29%)
AAPL   118.73 (-1.17%)
MSFT   227.17 (+0.19%)
FB   258.48 (+0.33%)
GOOGL   2,039.27 (+0.26%)
TSLA   567.35 (-8.70%)
AMZN   2,918.60 (-1.98%)
NVDA   474.65 (-4.07%)
BABA   230.23 (-0.12%)
CGC   29.05 (-6.32%)
GE   13.32 (-1.84%)
MU   84.48 (+0.18%)
NIO   34.60 (-11.91%)
AMD   75.35 (-3.09%)
T   29.42 (+1.73%)
F   11.90 (-0.25%)
ACB   8.96 (-8.76%)
DIS   185.12 (-1.55%)
BA   218.45 (-2.79%)
NFLX   502.77 (-1.67%)
BAC   36.50 (+0.00%)
S&P 500   3,741.80 (-0.71%)
DOW   30,853.89 (-0.23%)
QQQ   300.18 (-1.29%)
AAPL   118.73 (-1.17%)
MSFT   227.17 (+0.19%)
FB   258.48 (+0.33%)
GOOGL   2,039.27 (+0.26%)
TSLA   567.35 (-8.70%)
AMZN   2,918.60 (-1.98%)
NVDA   474.65 (-4.07%)
BABA   230.23 (-0.12%)
CGC   29.05 (-6.32%)
GE   13.32 (-1.84%)
MU   84.48 (+0.18%)
NIO   34.60 (-11.91%)
AMD   75.35 (-3.09%)
T   29.42 (+1.73%)
F   11.90 (-0.25%)
ACB   8.96 (-8.76%)
DIS   185.12 (-1.55%)
BA   218.45 (-2.79%)
NFLX   502.77 (-1.67%)
BAC   36.50 (+0.00%)
S&P 500   3,741.80 (-0.71%)
DOW   30,853.89 (-0.23%)
QQQ   300.18 (-1.29%)
AAPL   118.73 (-1.17%)
MSFT   227.17 (+0.19%)
FB   258.48 (+0.33%)
GOOGL   2,039.27 (+0.26%)
TSLA   567.35 (-8.70%)
AMZN   2,918.60 (-1.98%)
NVDA   474.65 (-4.07%)
BABA   230.23 (-0.12%)
CGC   29.05 (-6.32%)
GE   13.32 (-1.84%)
MU   84.48 (+0.18%)
NIO   34.60 (-11.91%)
AMD   75.35 (-3.09%)
T   29.42 (+1.73%)
F   11.90 (-0.25%)
ACB   8.96 (-8.76%)
DIS   185.12 (-1.55%)
BA   218.45 (-2.79%)
NFLX   502.77 (-1.67%)
BAC   36.50 (+0.00%)
Log in
NASDAQ:IFRX

InflaRx Stock Forecast, Price & News

$3.75
-0.04 (-1.06 %)
(As of 03/5/2021 10:53 AM ET)
Add
Compare
Today's Range
$3.67
Now: $3.75
$3.97
50-Day Range
$4.03
MA: $5.48
$6.34
52-Week Range
$2.52
Now: $3.75
$9.70
Volume11,525 shs
Average Volume440,901 shs
Market Capitalization$105.86 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
InflaRx logo

Headlines

InflaRx to Present at Upcoming Investor Conferences
March 3, 2021 |  finance.yahoo.com
InflaRx prices $75M capital raise - Seeking Alpha
February 25, 2021 |  seekingalpha.com
InflaRx launches stock offering - Seeking Alpha
February 25, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IFRX
CUSIPN/A
CIKN/A
Phone49-36-4150-8180
Employees43
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.62 per share

Profitability

Net Income$-59,650,000.00

Miscellaneous

Market Cap$105.86 million
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

618th out of 1,969 stocks

Pharmaceutical Preparations Industry

297th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
$3.75
-0.04 (-1.06 %)
(As of 03/5/2021 10:53 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











InflaRx (NASDAQ:IFRX) Frequently Asked Questions

Is InflaRx a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" InflaRx stock.
View analyst ratings for InflaRx
or view top-rated stocks.

What stocks does MarketBeat like better than InflaRx?

Wall Street analysts have given InflaRx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but InflaRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is InflaRx's next earnings date?

InflaRx is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for InflaRx
.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) posted its quarterly earnings results on Thursday, October, 29th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.07.
View InflaRx's earnings history
.

How has InflaRx's stock price been impacted by Coronavirus?

InflaRx's stock was trading at $3.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IFRX shares have increased by 16.1% and is now trading at $3.75.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for IFRX?

7 equities research analysts have issued 12-month target prices for InflaRx's stock. Their forecasts range from $7.00 to $19.00. On average, they expect InflaRx's share price to reach $11.17 in the next twelve months. This suggests a possible upside of 197.8% from the stock's current price.
View analysts' price targets for InflaRx
or view top-rated stocks among Wall Street analysts.

Who are InflaRx's key executives?

InflaRx's management team includes the following people:
  • Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 49)
  • Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 51)
  • Dr. Thomas Taapken Ph.D., Chief Financial Officer (Age 56)
  • Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy
  • Dr. Maria Habel PH.D., Head of Preclinical R&D (Age 39)
  • Ms. Katrin Reiher, Head of Quality Management (Age 39)
  • Mr. Jordan Zwick, Chief Strategy Officer
  • Dr. Korinna Pilz, Global Head of Clinical R&D

Who are some of InflaRx's key competitors?

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), (KDMN) and Moderna (MRNA).

When did InflaRx IPO?

(IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

Who are InflaRx's major shareholders?

InflaRx's stock is owned by many different institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (3.26%), Orbimed Advisors LLC (2.12%), Bank Julius Baer & Co. Ltd Zurich (0.75%), Renaissance Technologies LLC (0.53%), Verition Fund Management LLC (0.38%) and Raymond James Financial Services Advisors Inc. (0.13%).

Which major investors are selling InflaRx stock?

IFRX stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Orbimed Advisors LLC, and Raymond James Financial Services Advisors Inc..

Which major investors are buying InflaRx stock?

IFRX stock was acquired by a variety of institutional investors in the last quarter, including Bank Julius Baer & Co. Ltd Zurich, Renaissance Technologies LLC, Franklin Street Advisors Inc. NC, JPMorgan Chase & Co., and Verition Fund Management LLC.

How do I buy shares of InflaRx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $3.75.

How much money does InflaRx make?

InflaRx has a market capitalization of $105.86 million. The company earns $-59,650,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does InflaRx have?

InflaRx employs 43 workers across the globe.

What is InflaRx's official website?

The official website for InflaRx is www.inflarx.de.

Where are InflaRx's headquarters?

InflaRx is headquartered at WINZERLAER STR. 2, JENA 2M, 07745.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.